Following a slight delay earlier this year—and a world-first green light in the U.K. over the summer—Bayer has clinched an FDA nod to bolster the limited arsenal of nonhormonal treatments for one of the most common symptoms of menopause. More:
read moreIpsen unveiled a new educational initiative dedicated to supporting teenagers and young adults in the transition from their pediatricians to adult care, for which they’re often unprepared. More: Ipsen's educational push offers guidance to young adults switching from pediatric to
read moreOver the last 13 months, Sanofi and Regeneron have revved up the momentum for Dupixent, gaining three new indications for the anti-inflammatory agent. On Friday, Sanofi reported that Dupixent achieved a new standard as quarterly sales exceeded 4 billion euros
read moreA cystic fibrosis buyers group has resurfaced in a bid to improve access to Vertex’s expensive combination therapy Trikafta. Under the strategy, a much cheaper copycat of the modulator drug is slated to launch next spring and will be manufactured
read moreLast year, Japan’s Renalys picked up certain Asian rights to the IgAN medicine sparsentan from the medicine’s developer, Travere Therapeutics. Chugai is set to take the medicine forward in the licensed countries under a new M&A deal. More: Roche's Chugai
read more© 1994 - 2025 B.M. Pharmaceuticals